Table 1.
Collection of protein kinase inhibitors used for CD39 screening
| # | Drug | Trade name | CAS-number | Target |
| 1 | Abemaciclib | Verzenio | 1231929-97-7 | CDK4/6 |
| 2 | Acalabrutinib | Calquence | 1420477-60-6 | Bruton tyrosine kinase |
| 3 | Afatinib | Tovok | 850140-72-6 | EGFR, ErbB2, ErbB4 |
| 4 | Alectinib | Alecensa | 1256580-46-7 | ALK and RET |
| 5 | Axitinib | Inlyta | 319460-85-0 | VEGFR1/2/3, PDGFRβ |
| 6 | Baricitinib | Olumiant | 1187594-09-7 | JAK1/2 |
| 7 | Binimetinib | Mektovi | 606143-89-9 | MEK1/2 |
| 8 | Bosutinib | BOSULIF | 380843-75-4 | BCR-Abl, Src, Lyn, and Hck |
| 9 | Brigatinib | Alunbrig | 1197953-54-0 | ALK, ROS1, IGF-1R, Flt3, EGFR |
| 10 | Cabozantinib | Cometriq | 849217-68-1 | RET, MET, VEGFR1/2/3, Kit, TrkB, Flt3, Axl, Tie2 |
| 11 | Ceritinib | Zykadia | 1032900-25-6 | ALK, IGF-1R, InsR, ROS1 |
| 12 | Cobimetinib | Cotellic | 934660-93-2 | MEK1/2 |
| 13 | Crizotinib | Xalkori | 877399-52-5 | ALK, MET (HGFR), ROS1, MST1R |
| 14 | Dabrafenib | Tafinlar | 1195765-45-7 | B-Raf |
| 15 | Dacomitinib | Visimpro | 1110813-31-4 | EGFR family |
| 16 | Dasatinib | Sprycel | 302962-49-8 | BCR-Abl, EGFR, Src, Lck, Yes, Fyn, Kit, EphA2, PDGFRβ |
| 17 | Encorafenib | Braftovi | 1269440-17-6 | B-Raf |
| 18 | Erdafitinib | Balversa | 1346242-81-6 | FGFR1/2/3/4 |
| 19 | Erlotinib | Tarceva | 183319-69-9 | EGFR |
| 20 | Everolimus | Afinitor | 159351-69-6 | FKBP12/mTOR |
| 21 | Fostamatinib | Tavalisse | 901119-35-5 | Syk, Spleen tyrosine kinase |
| 22 | Gefitinib | Iressa | 184475-35-2 | EGFR |
| 23 | Gilteritinib | Xospata | 1254053-43-4 | Flt3 |
| 24 | Ibrutinib | Imbruvica | 936563-96-1 | Bruton tyrosine kinase |
| 25 | Idelalisib | Zydelig | 870281-82-6 | Phosphatidylinositol-3- Kinase |
| 26 | Imatinib | Gleevec | 152459-95-5 | BCR-Abl, Kit, and PDGFR |
| 27 | Lapatinib | Tykerb | 231277-92-2 | EGFR, ErbB2 |
| 28 | Larotrectinib | Vitrakvi | 1223403-58-4 | TRK |
| 29 | Lenvatinib | Lenvima | 417716-92-8 | VEGFR1/2/3, PDGFR, FGFR, Kit, RET |
| 30 | Lorlatinib | Lorbrena | 1454846-35-5 | ALK |
| 31 | Midostaurin | Rydapt | 120685-11-2 | Flt3, PDGFR, VEGFR2, PKC |
| 32 | Neratinib | Nerlynx | 698387-09-6 | ErbB2/HER2 |
| 33 | Nilotinib | Tasigna | 641571-10-0 | BCR-Abl, PDGFR, DDR1 |
| 34 | Nintedanib | Vargatef | 656247-17-5 | FGFR1/2/3, PDGFRα/β, VEGFR1/2/3, Flt3 |
| 35 | Osimertinib | Tagrisso | 1421373-65-0 | EGFR T970M |
| 36 | Palbociclib | Ibrance | 571190-30-2 | CDK4/6 |
| 37 | Pazopanib | Votrient | 444731-52-6 | VEGFR1/2/3, PDGFRα/β, FGFR1/3, Kit, Lck, Fms, Itk |
| 38 | Ponatinib | Iclusig | 943319-70-8 | BCR-Abl, BCR-Abl T315I, VEGFR, PDGFR, FGFR, EphR, Src family kinases, Kit, RET, Tie2, Flt3 |
| 39 | Regorafenib | Stivarga | 755037-03-7 | VEGFR1/2/3, BCR-Abl, B-Raf, B-Raf (V600E), Kit, PDGFRα/β, RET, FGFR1/2, Tie2, and Eph2A |
| 40 | Ribociclib | Kisqali | 1211441-98-3 | CDK4/6 |
| 41 | Ruxolitinib | Jakafi | 941678-49-5 | JAK1/2 |
| 42 | Sirolimus | Rapamycin | 53123-88-9 | FKBP/mTOR |
| 43 | Sorafenib | Nexavar | 284461-73-0 | VEGFR1/2/3, B-/C-Raf, mutant B-Raf, Kit, Flt3, RET, and PDGFRß |
| 44 | Sunitinib | Sutent | 557795-19-4 | PDGFRα/β, VEGFR1/2/3, Kit, Flt3, CSF-1R, Axl, and RET |
| 45 | Temsirolimus | Torisel | 162635-04-3 | FKBP12/mTOR |
| 46 | Tivozanib | Fotivda | 475108-18-0 | Multikinase inhibitor, eg, VEGF receptor tyrosine kinase |
| 47 | Tofacitinib | Tasocitinib | 477600-75-2 | JAK3 |
| 48 | Trametinib | Mekinist | 871700-17-3 | MEK1/2 |
| 49 | Vandetanib | Zactima | 443913-73-3 | RET, EGFRs, VEGFRs, Brk, Tie2, EphRs, and Src family kinases |
| 50 | Vemurafenib | Zelboraf | 918504-65-1 | A/B/C-Raf and B-Raf (V600E) |